Related Experiment Videos
Etoposide as the basic and interferon-alpha as the maintenance therapy for Langerhans cell histiocytosis: a RTC.
1Department of Pediatrics, Pediatric Hemato-Oncology, Clinical Hospital Split, Split, Croatia. srdjana.culic@st.tel.hr
Pediatric Hematology and Oncology
|June 13, 2001
Summary
This study suggests etoposide followed by interferon-alpha (IFN-alpha) can achieve remission in high-risk disseminated Langerhans cell histiocytosis (LCH). IFN-alpha may prevent recurrences in these young patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Immunology
Background:
- Treatment for disseminated Langerhans cell histiocytosis (LCH) remains controversial, with limited large-scale randomized studies.
- Disseminated LCH in infants and young children often presents with high-risk factors and poor prognosis.
Observation:
- Three young patients (4 months, 9 months, 2 years) with disseminated LCH were studied.
- Lesional Langerhans cells showed positive S-100 protein immunohistochemistry and confirmed Birbeck granules via electron microscopy.
- Patients presented with multiple-organ involvement, and two had signs of organ dysfunction.
Findings:
- All patients received etoposide (VP-16) chemotherapy followed by interferon-alpha (IFN-alpha) maintenance therapy.
- Complete and stable remission was achieved in all three patients.
- Patients remained disease-free for several years post-treatment.
Implications:
- Etoposide combined with IFN-alpha appears effective for high-risk disseminated LCH.
- IFN-alpha may play a crucial role in preventing disease recurrence in pediatric LCH patients.
- This regimen offers a potential therapeutic strategy for severe LCH cases.